CTLT

Catalent, Inc. (CTLT) | Rumor.io

Catalent

CTLT

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)100%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about CTLT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% +0	0% +0

Mar 16

Catalent, Inc. (CTLT) is mentioned as an example of a company that investors can be fearful of, implying a potential undervaluation.
No specific market-relevant information is provided about Catalent, Inc. in the given post.
The post does not provide any specific price targets or predictions for Catalent, Inc.

Generated by AI

Sentiment

Of the messages about CTLT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	91.74% +33.48
Bearish	—	—	—	8.26% -33.48

Bullish· Feb 5

Catalent's acquisition by Novo Holdings at $63.50 per share is expected to increase Wegovy output, a key factor in Novo Nordisk's growth.
The deal is seen as a strategic move by Novo Nordisk to vertically integrate and consolidate the obesity market, with Catalent's manufacturing facilities playing a key role.
The acquisition is viewed as a bargain for Novo Nordisk, with some analysts predicting a 75% return on investment, citing the company's history of aggressive trades and bullish options activity.

Bearish· Oct 31

Catalent $CTLT is experiencing a significant price drop, down -14.70% with above-average trading volume.
The company's sales may be impacted by Sarepta Therapeutics' (SRPT) disappointing topline results, potentially leading to a loss of estimated $50 million sales.
The market's reaction to Catalent's potential loss of revenue is seen as an overreaction, with some viewing it as a minor issue compared to the company's overall sales and contracts.

Generated by AI

Topics

Of the messages about CTLT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	0%	0%	0%	0.11%
Announcements	100%	100%	100%	37.8%
Controversies	0%	0%	0%	19.34%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	42.75%
Technical Analysis	0%	0%	0%	0%

Earnings· May 8

Catalent, Inc. ($CTLT) delays earnings, reducing fiscal 2023 net revenue and Adjusted EBITDA guidance by more than $400 million each due to identified significant issues with its forecasts and productivity issues at 3 facilities.
The company's CFO has been fired, and investors should be aware of a heightened risk of restatement, with debt covenants also a concern.
Catalent expects to significantly reduce both its fiscal 2023 net revenue and Adjusted EBITDA guidance by more than $400 million each, with a goodwill impairment of over $200 million related to its October 2021 acquisition of Bettera Wellness.

Analysts· May 22

Catalent's stock has been downgraded by JPMorgan to Neutral due to limited near-term visibility.
Morgan Stanley has lowered the price target for Catalent to $50, while Deutsche Bank has raised its price target to $37.
Robert W. Baird has cut its price target for Catalent to $35, while Deutsche Bank has maintained a Hold rating with a price target of $37.

Announcements· Dec 16

Catalent, Inc. ($CTLT) is set to be acquired by Novo Holdings ($NVO) for $16.5 billion after the Federal Trade Commission (FTC) review was completed.
The acquisition is expected to support the production of Ozempic and Wegovy diabetes and obesity medications.
Novo Nordisk plans to invest over $1 billion in a new Denmark production facility, and is closer to acquiring three additional sites from Catalent.

Technical Analysis· Nov 6

$CTLT technical alerts include Non-ADX 1,2,3,4 Bullish and 6 more alerts.
A swing trade alert has been issued for $CTLT based on recent technical signals.
The alerts for $CTLT are part of a larger list of technical alerts.

Generated by AI

Community

Of the messages about CTLT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	9.09%	9.09%	9.09%	0.6%
Newcomers	90.91%	90.91%	90.91%	99.4%

Regulars· Feb 9

Catalent's sales continue to slide as it prepares to join Novo, with adjusted EPS missing estimates by 22 cents.
The company's Q2 non-GAAP EPS of -$0.24 and revenue of $1.03B beat estimates but missed on EPS and saw a -10.4% Y/Y revenue decline.
Despite the decline, Royal Bank of Canada reaffirmed its Sector Perform rating for Catalent, with analysts citing the company's potential for future growth if it maximizes current utilization.

Newcomers· Jul 30

The newcomer is concerned about the potential impact of the FDA on the generics market, which could benefit Novo Nordisk's business.
The newcomer notes that Novo Nordisk's stock is cheaply priced at a 14 TTM P/E ratio, but this could change if the FDA cracks down on generics.
The newcomer highlights Catalent's acquisition of factories as a potential positive for Novo Nordisk, but notes that tariffs could also benefit the company since they export more from the U.S. than they import.

Generated by AI

CD&R (or the "Firm") today announced that John Chiminski, former Chair and Chief Executive Officer of Catalent, Inc., has been engaged as an Operating Advisor to CD&R funds. John brings more than three decades of leadership experience across the healthcare, pharmaceutical and pharma services sectors and will advise the Firm on investment opportunities and value-creation initiatives within its healthcare vertical.

2mo agoYahoo Finance

Catalent and Nanoscope Therapeutics Expand Partnership to Support Late-Phase Development and Commercial Supply of MCO-010

TAMPA, Fla. & DALLAS, July 07, 2026--Catalent & Nanoscope Therapeutics Expand Partnership to Support Late-Phase Development and Commercial Supply of Lead Optogenetic Gene Therapy, MCO-010

2mo agoYahoo Finance

Also Discussed

Investors talking about CTLT also mention

#	Name	Attention
1	Scholar Rock Holding Corporation Common StockSRRK	0%new
2	AMWD - American Woodmark Corporation	——
3	MarketAxess Holdings Inc.MKTX	0%0
4	Cimpress plcCMPR	0%0
5	Avantor, Inc.AVTR	0%0
6	AstraZeneca PLC American Depositary SharesAZN	0.02%+0.02
7	SGEN - Seagen Inc.	——
8	MRTX - Mirati Therapeutics, Inc.	——
9	Carmell CorporationCTCX	0%0
10	IQVIA Holdings Inc.IQV	0%0

Catalent, Inc.

Location

Social

What share of all stock conversation is about CTLT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% +0	0% +0

Mar 16

Catalent, Inc. (CTLT) is mentioned as an example of a company that investors can be fearful of, implying a potential undervaluation.
No specific market-relevant information is provided about Catalent, Inc. in the given post.
The post does not provide any specific price targets or predictions for Catalent, Inc.

Generated by AI

Sentiment

Of the messages about CTLT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	91.74% +33.48
Bearish	—	—	—	8.26% -33.48

Bullish· Feb 5

Catalent's acquisition by Novo Holdings at $63.50 per share is expected to increase Wegovy output, a key factor in Novo Nordisk's growth.
The deal is seen as a strategic move by Novo Nordisk to vertically integrate and consolidate the obesity market, with Catalent's manufacturing facilities playing a key role.
The acquisition is viewed as a bargain for Novo Nordisk, with some analysts predicting a 75% return on investment, citing the company's history of aggressive trades and bullish options activity.

Bearish· Oct 31

Catalent $CTLT is experiencing a significant price drop, down -14.70% with above-average trading volume.
The company's sales may be impacted by Sarepta Therapeutics' (SRPT) disappointing topline results, potentially leading to a loss of estimated $50 million sales.
The market's reaction to Catalent's potential loss of revenue is seen as an overreaction, with some viewing it as a minor issue compared to the company's overall sales and contracts.

Generated by AI

Topics

Of the messages about CTLT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	0%	0%	0%	0.11%
Announcements	100%	100%	100%	37.8%
Controversies	0%	0%	0%	19.34%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	42.75%
Technical Analysis	0%	0%	0%	0%

Earnings· May 8

Catalent, Inc. ($CTLT) delays earnings, reducing fiscal 2023 net revenue and Adjusted EBITDA guidance by more than $400 million each due to identified significant issues with its forecasts and productivity issues at 3 facilities.
The company's CFO has been fired, and investors should be aware of a heightened risk of restatement, with debt covenants also a concern.
Catalent expects to significantly reduce both its fiscal 2023 net revenue and Adjusted EBITDA guidance by more than $400 million each, with a goodwill impairment of over $200 million related to its October 2021 acquisition of Bettera Wellness.

Analysts· May 22

Catalent's stock has been downgraded by JPMorgan to Neutral due to limited near-term visibility.
Morgan Stanley has lowered the price target for Catalent to $50, while Deutsche Bank has raised its price target to $37.
Robert W. Baird has cut its price target for Catalent to $35, while Deutsche Bank has maintained a Hold rating with a price target of $37.

Announcements· Dec 16

Catalent, Inc. ($CTLT) is set to be acquired by Novo Holdings ($NVO) for $16.5 billion after the Federal Trade Commission (FTC) review was completed.
The acquisition is expected to support the production of Ozempic and Wegovy diabetes and obesity medications.
Novo Nordisk plans to invest over $1 billion in a new Denmark production facility, and is closer to acquiring three additional sites from Catalent.

Technical Analysis· Nov 6

$CTLT technical alerts include Non-ADX 1,2,3,4 Bullish and 6 more alerts.
A swing trade alert has been issued for $CTLT based on recent technical signals.
The alerts for $CTLT are part of a larger list of technical alerts.

Generated by AI

Community

Of the messages about CTLT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	9.09%	9.09%	9.09%	0.6%
Newcomers	90.91%	90.91%	90.91%	99.4%

Regulars· Feb 9

Catalent's sales continue to slide as it prepares to join Novo, with adjusted EPS missing estimates by 22 cents.
The company's Q2 non-GAAP EPS of -$0.24 and revenue of $1.03B beat estimates but missed on EPS and saw a -10.4% Y/Y revenue decline.
Despite the decline, Royal Bank of Canada reaffirmed its Sector Perform rating for Catalent, with analysts citing the company's potential for future growth if it maximizes current utilization.

Newcomers· Jul 30

The newcomer is concerned about the potential impact of the FDA on the generics market, which could benefit Novo Nordisk's business.
The newcomer notes that Novo Nordisk's stock is cheaply priced at a 14 TTM P/E ratio, but this could change if the FDA cracks down on generics.
The newcomer highlights Catalent's acquisition of factories as a potential positive for Novo Nordisk, but notes that tariffs could also benefit the company since they export more from the U.S. than they import.

Generated by AI

Catalent

Social

Mar 16

Sentiment

Bullish· Feb 5

Bearish· Oct 31

Topics

Earnings· May 8

Analysts· May 22

Announcements· Dec 16

Technical Analysis· Nov 6

Community

Regulars· Feb 9

Newcomers· Jul 30

News

John Chiminski, Former Catalent Chair and CEO, to Serve as CD&R Operating Advisor

Catalent and Nanoscope Therapeutics Expand Partnership to Support Late-Phase Development and Commercial Supply of MCO-010

Also Discussed

Catalent, Inc.

Company Information

Location

News

John Chiminski, Former Catalent Chair and CEO, to Serve as CD&R Operating Advisor

Catalent and Nanoscope Therapeutics Expand Partnership to Support Late-Phase Development and Commercial Supply of MCO-010

Also Discussed

Social

Mar 16

Sentiment

Bullish· Feb 5

Bearish· Oct 31

Topics

Earnings· May 8

Analysts· May 22

Announcements· Dec 16

Technical Analysis· Nov 6

Community

Regulars· Feb 9

Newcomers· Jul 30